The FDA-cleared GammaTile radioactive implant is redefining treatment for brain metastases by delivering radiation directly to surgical sites immediately after tumor removal. Recent Phase III clinical trial data shows the technology significantly reduces surgical bed recurrence and more than doubles median overall survival compared to standard postoperative stereotactic radiation therapy.
For decades, the standard of care for operable brain metastases followed a rigid sequence: surgical resection, a multi-week recovery period, and then postoperative stereotactic radiosurgery (SRS). This gap in care often delayed systemic treatment and left a window where residual microscopic tumor cells could proliferate. The ROADS (Radiation One and Done Study) Phase III trial has challenged this paradigm, suggesting that the timing of radiation may be as critical as the technology itself.
The ROADS Trial: Comparing TBRT to Standard Care
The ROADS trial, presented at the 2026 ASCO Annual Meeting, enrolled 230 patients across 32 medical centers. Researchers compared tile-based radiation therapy (TBRT) — using GammaTiles implanted during surgery — against the traditional approach of delivering stereotactic radiation therapy (SRT) two to four weeks after the operation. The results indicate a stark difference in local control.
| Metric | TBRT (GammaTile) | Standard SRT |
|---|---|---|
| 12-Month Surgical Bed Recurrence | 1.3% | 15.4% |
| Median Overall Survival | More than doubled | Baseline |
| Surgical Bed Recurrence-Free Survival | Median not reached | 10.9 months |
According to Allegheny Health Network neurosurgeon Matt Shepard, approximately 20-30% of patients struggle to return for radiation weeks after surgery due to health concerns or transportation issues. By integrating radiation into the initial surgery, the definitive local therapy was completed in a median of one day, compared to approximately 30 days for the SRT group.
GammaTile Mechanism and Surgical Application
GammaTiles are biocompatible, flexible collagen squares roughly the size of a postage stamp. These tiles are embedded with titanium-encapsulated cesium-131 brachytherapy seeds. Once implanted into the surgical cavity, the seeds deliver a highly focal dose of radiation — approximately 100 to 120 Gy to the cavity wall — with about 90% of the dose delivered within the first 33 days. The radioactive seeds completely decay after 100 days, and the collagen tiles are absorbed by the body over time.
The immediate placement of these tiles targets the microscopic spillage
of tumor cells that often linger even when a surgeon successfully removes a mass in one piece. This is particularly vital for tumors located near critical speech or movement centers, where total removal is dangerous. By treating the site before the incision is closed, surgeons eliminate the postoperative microenvironment of wound healing and inflammation that may otherwise contribute to tumor repopulation.
Clinical Implementation at AHN and OHSU
At Oregon Health & Science University (OHSU), which recently became the first in Oregon to use the device, clinicians identify two primary beneficiary groups. The first includes patients with recurrent gliomas or metastasis where additional external beam radiation would be too toxic. The second group consists of those undergoing surgical removal for the first time, for whom the tiles eliminate the need for subsequent external radiation.
In Western Pennsylvania, the Allegheny Health Network has already treated patients like Tony Parise. Parise received five implants in 2023 and an additional 3½ tiles following a second tumor removal in 2024. This aligns with ROADS trial findings, which indicated that rates of radiation toxicity and surgical complications were identical to those of traditional postoperative treatment.
The Shift Toward Single-Procedure Local Therapy
The transition from a multi-step process to a single-procedure model represents a significant shift in neuro-oncology. By collapsing the timeline, physicians can potentially initiate systemic therapies sooner and remove the risk of patients missing their radiation window entirely.
While the ROADS trial provides a strong foundation, clinicians continue to monitor the long-term effects of continuous low-dose-rate irradiation. The current evidence suggests that by treating the residual disease when the burden is at its lowest — immediately after resection — the medical community may have found a way to significantly lower the risk of recurrence without increasing the toxicity of the treatment.
Keep reading
